Selected Drugs Clear All
MultiCheck Results
- 0
Interaction
Additional Considerations |
||
|
epcoritamab
in Epkinly (epcoritamab-bysp)
|
||
|
caution advised with narrow therapeutic index drugs metabolized by CYP450 liver enzymes, especially at initiation and up to 14 days after first 48 mg dose on Day 15 of Cycle 1 or during/after CRS; epcoritamab may transiently increase cytokine release leading to suppression of CYP450 metabolic function, causing incr. levels of concomitant drugs, risk of adverse effects |
||
|
Saccharomyces boulardii
in probiotic (Saccharomyces spp.)
|
||
|
caution advised; combo with antifungals may decr. Saccharomyces boulardii efficacy |
||